Table 1.
Clinical data and sources
| Clinical data | Data (%) | References |
|---|---|---|
| Remission rate in first therapeutic step | ||
| SNRIsa | ||
| Duloxetine | 44.99 | Wessling and Ramsberg (TLV) [1] |
| Venlafaxine | 45.68 | Wessling and Ramsberg (TLV) [1] |
| Mirtazapine | 45.08 | Wessling and Ramsberg (TLV) [1] |
| SSRIs | ||
| Citalopram | 40.50 | Wessling and Ramsberg (TLV) [1] |
| Escitalopram | 47.56 | Wessling and Ramsberg (TLV) [1] |
| Fluoxetine | 40.21 | Wessling and Ramsberg (TLV) [1] |
| Paroxetine | 42.70 | Wessling and Ramsberg (TLV) [1] |
| Sertraline | 43.02 | Wessling and Ramsberg (TLV) [1] |
| Remission rate in second therapeutic step | ||
| Switch to SNRI (venlafaxine 75 mg/day) | 25.00 | Rush et al. (STAR*D) [18] |
| Switch to SSRI (sertraline 50 mg/day) | 26.60 | Rush et al. (STAR*D) [18] |
| Switch to psychotherapy | 41.90 | Rush et al. (STAR*D) [18] |
| Combination with bupropion 150 mg/day | 39.00 | Rush et al. (STAR*D) [18] |
| Combination with psychotherapy | 29.40 | Rush et al. (STAR*D) [18] |
| Augmentation with quetiapine 300 mg/day | 53.10 | Bauer et al. [19] |
| Titration | ||
| SNRIsa | ||
| Duloxetine | NA | |
| Venlafaxine | 37.40 | Francois et al. [20] |
| Mirtazapine | 36.91 | Francois et al. [20] |
| SSRIs | ||
| Citalopram | 23.80 | Francois et al. [20] |
| Escitalopram | 36.20 | Francois et al. [20] |
| Fluoxetine | 23.80 | Francois et al. [20] |
| Paroxetine | 32.50 | Francois et al. [20] |
| Sertraline | 32.74 | Francois et al. [20] |
| Risk of relapse | ||
| Similar across treatment | 14.20 | Limosin et al. [16] |
| Risk of suicide | ||
| Attempted suicide | 6.30 | Kahn et al. [17] |
| Death after suicide attempt | 10.00 | Kahn et al. [17] |
NA not applicable, SNRI serotonin–norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor, TLV Tandvårds- och läkemedelsförmånsverket
aSNRI: including mirtazapine